Intervention Review

You have free access to this content

Rivastigmine for vascular cognitive impairment

  1. Jacqueline Birks1,*,
  2. Bernadette McGuinness2,
  3. David Craig3

Editorial Group: Cochrane Dementia and Cognitive Improvement Group

Published Online: 31 MAY 2013

Assessed as up-to-date: 12 FEB 2013

DOI: 10.1002/14651858.CD004744.pub3


How to Cite

Birks J, McGuinness B, Craig D. Rivastigmine for vascular cognitive impairment. Cochrane Database of Systematic Reviews 2013, Issue 5. Art. No.: CD004744. DOI: 10.1002/14651858.CD004744.pub3.

Author Information

  1. 1

    University of Oxford, Centre for Statistics in Medicine, Oxford, UK

  2. 2

    National University of Ireland, School of Medicine, Galway, Ireland

  3. 3

    Queen's University Belfast, Department of Geriatric Medicine, Belfast, Northern Ireland, UK

*Jacqueline Birks, Centre for Statistics in Medicine, University of Oxford, Wolfson College, Linton Road, Oxford, OX2 6UD, UK. jacqueline.birks@csm.ox.ac.uk.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 31 MAY 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. Additional references
  3. References to other published versions of this review
Ballard 2008 {published data only}
  • Ballard C, Sauter M, Scheltens P, He Y, Barkhof F, van Straaten EC, et al. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Current medical research and opinion 2008;24(9):2561-74. [PUBMED: 18674411]
Mok 2007 {published data only}
  • Mok V, Wong A, Ho S, Leung T, Lam WWM, Wong KS. Rivastigmine in Chinese patients with subcortical vascular dementia. Neuropsychiatric Disease and Treatment 2007;3(6):943-8.
Narasimhalu 2010 {published data only}

Additional references

  1. References to studies included in this review
  2. Additional references
  3. References to other published versions of this review
Black 2011
  • Black SE. Vascular cognitive impairment: epidemiology, subtypes, diagnosis and management. The journal of the Royal College of Physicians of Edinburgh 2011;41(1):49-56. [PUBMED: 21365068]
Bruandet 2009
  • Bruandet A, Richard F, Bombois S, Maurage CA, Deramecourt V, Lebert F, et al. Alzheimer disease with cerebrovascular disease and vascular dementia: clinical features and course compared with Alzheimer disease. Journal of Neurology, Neurosurgery, and Psychiatry 2009;80(2):133-9. [PUBMED: 18977819]
Bullock 2004
Chiu 1994
  • Chiu HFK, Lee HC, Chung WS, Kwong PK. The reliability and validity of the Cantonese version of Mini-Mental State Examination. East Asian Archives of Psychiatry: Official Journal of the Hong Kong College of Psychiatrists 1994;4 (Supp 2):25-8.
Chui 1992
  • Chui H, Victoroff J, Margolin D, Jagust W, Shankle R, Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 1992;42(3 Part 1):473-80.
Cummings 1993
D'elia 1996
  • D'elia LSP, Uchiyama CL, White T. Colour Trails Test. Psychological Assessment Resources Inc. PAR, 1996.
Dubois 2000
Erkinjuntti 2000
  • Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, et al. Research criteria for subcortical vascular dementia in clinical trials. Journal of Neural Transmission 2000;59(Suppl):23-30.
Ferris 1999
Folstein 1975
Galasko 1997
  • Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders 1997;11 Suppl 2:S33-9. [PUBMED: 9236950]
Hansen 2008
  • Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clinical Interventions in Aging 2008;3(2):211-25. [PUBMED: 18686744]
Higgins 2011
  • Higgins JPT, Green S (Editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.
Kerola 2010
  • Kerola T, Kettunen R, Nieminen T. The complex interplay of cardiovascular system and cognition: How to predict dementia in the elderly?. International Journal of Cardiology 2010;150(2):123-9. [PUBMED: 21094551]
Kivipelto 2005
  • Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kareholt I, Winblad B, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Archives of Neurology 2005;62(10):1556-60. [PUBMED: 16216938]
Leung 2001
Malouf 2004
Manos 1994
  • Manos PJ, Wu R. The ten point clock test: a quick screen and grading method for cognitive impairment in medical and surgical patients. International Journal of Psychiatry in Medicine 1994;24(3):229-44. [PUBMED: 7890481]
Mok 2004
  • Mok VC, Wong A, Yim P, Fu M, Lam WW, Hui AC, et al. The validity and reliability of chinese frontal assessment battery in evaluating executive dysfunction among Chinese patients with small subcortical infarct. Alzheimer Disease and Associated Disorders 2004;18:68-74.
Moretti 2004
Morris 1993
MRC CFAS 2001
  • Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. The Lancet 2001;357:169-75.
O'Brien 2000
O'Brien 2003
Perry 1997
Pohjasvaara 2003
  • Pohjasvaara T, Mantyla R, Ylikoski R, Kaste M, Erkinjuntti T. Clinical features of MRI-defined subcortical vascular disease. Alzheimer Disease and Associated Disorders 2003;17(4):236-42.
Reisberg 1982
Roman 1993
  • Roman G, Tatemichi T, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43(2):250-60.
Rosen 1984
Schneider 1997
  • Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders 1997;11 Suppl 2:S22-32. [PUBMED: 9236949]
Toghi 1996
  • Toghi H, Abe T, Kimura M, Saheki M, Takahashi S. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarcts types as compared with Alzheimer-type dementia. Journal of Neural Transmission 1996;103:1211-20.
Tong 2002
  • Tong AYC, Man DWK. The Validation of the Hong Kong Chinese Version of the Lawton Instrumental Activities of Daily Living Scale for institutionalized elderly persons.. Occupation, Participation and Health 2002;22(4):132.
WHO 1992
  • World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Description and Diagnostic Guidelines. 10th Edition. Geneva: World Health organiazation, 1992.
Yesavage 1982
  • Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. Journal of Psychiatric Research 1982;17(1):37-49. [PUBMED: 7183759]

References to other published versions of this review

  1. References to studies included in this review
  2. Additional references
  3. References to other published versions of this review
Craig 2004
  • Craig D, Birks J. Rivastigmine for vascular cognitive impairment 10.1002/14651858.CD004744.pub2. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD004744.pub2]